JP2019537617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537617A5 JP2019537617A5 JP2019528444A JP2019528444A JP2019537617A5 JP 2019537617 A5 JP2019537617 A5 JP 2019537617A5 JP 2019528444 A JP2019528444 A JP 2019528444A JP 2019528444 A JP2019528444 A JP 2019528444A JP 2019537617 A5 JP2019537617 A5 JP 2019537617A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain variable
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 102000013691 Interleukin-17 Human genes 0.000 claims 3
- 108050003558 Interleukin-17 Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- -1 including Substances 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710602383.3A CN108359011B (zh) | 2017-07-21 | 2017-07-21 | 靶向于白介素17a的抗体、其制备方法和应用 |
| CN201710602383.3 | 2017-07-21 | ||
| PCT/CN2018/073458 WO2019015282A1 (zh) | 2017-07-21 | 2018-01-19 | 靶向于白介素17a的抗体、其制备方法和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537617A JP2019537617A (ja) | 2019-12-26 |
| JP2019537617A5 true JP2019537617A5 (enExample) | 2021-04-01 |
| JP6865826B2 JP6865826B2 (ja) | 2021-04-28 |
Family
ID=63009922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528444A Active JP6865826B2 (ja) | 2017-07-21 | 2018-01-19 | インターロイキン１７ａを標的とする抗体、その製造方法及び応用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10981983B2 (enExample) |
| EP (1) | EP3656789A4 (enExample) |
| JP (1) | JP6865826B2 (enExample) |
| CN (1) | CN108359011B (enExample) |
| WO (1) | WO2019015282A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| CN110585430B (zh) * | 2019-09-29 | 2023-09-08 | 华博生物医药技术（上海）有限公司 | 一种人源化抗人il-17a单克隆抗体的药物组合物 |
| CN113769082A (zh) * | 2020-06-10 | 2021-12-10 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体药物组合物及其用途 |
| CN112300285B (zh) * | 2020-11-06 | 2022-08-02 | 江苏荃信生物医药股份有限公司 | 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法 |
| EP4289863A4 (en) * | 2020-12-17 | 2025-04-09 | Shanghai Huaota Biopharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF |
| CN114920838B (zh) * | 2022-03-25 | 2023-11-24 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
| CN115819579B (zh) * | 2022-11-10 | 2023-11-07 | 浙江大学 | 全人源抗白介素17A单链抗体No.34及应用 |
| EP4631522A1 (en) | 2022-12-09 | 2025-10-15 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Il-17a antibody formulation and use thereof |
| EP4653009A1 (en) * | 2023-01-19 | 2025-11-26 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Method for treating systemic lupus erythematosus |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| EP2526968A3 (en) | 2006-01-27 | 2013-05-22 | Biogen Idec MA Inc. | Nogo receptor antagonists |
| NZ594514A (en) * | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| WO2011053763A2 (en) * | 2009-10-30 | 2011-05-05 | Centocor Ortho Biotech Inc. | Il-17a antagonists |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| LT2953969T (lt) * | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| US9862765B2 (en) * | 2013-11-18 | 2018-01-09 | Shanghai Hengrui Pharmaceutical Co., Ltd. | IL-17A binding agent and uses thereof |
| RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
-
2017
- 2017-07-21 CN CN201710602383.3A patent/CN108359011B/zh active Active
-
2018
- 2018-01-19 US US16/461,128 patent/US10981983B2/en active Active
- 2018-01-19 JP JP2019528444A patent/JP6865826B2/ja active Active
- 2018-01-19 WO PCT/CN2018/073458 patent/WO2019015282A1/zh not_active Ceased
- 2018-01-19 EP EP18835131.6A patent/EP3656789A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12116405B2 (en) | Arthritis treatment | |
| CN107667115B (zh) | 针对埃博拉病毒糖蛋白的人抗体 | |
| ES2784131T3 (es) | Polipéptidos de unión beta del receptor PDGF | |
| CN110167960B (zh) | 针对金黄色葡萄球菌溶血素a毒素的人类抗体 | |
| ES2352180T3 (es) | Anticuerpo monoclonal de anti-tenascina humana. | |
| US11655286B2 (en) | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof | |
| JP2006511516A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| JP2025183307A5 (enExample) | ||
| IL297619A (en) | Use of a multimeric anti-dr5 binding compound in combination with cancer therapy for the treatment of cancer | |
| EP4658676A2 (en) | Anti-cdh17 antibodies and use of the same | |
| CN104684929A (zh) | 治疗血管疾病及其并发症 | |
| CN117769434A (zh) | 与C1s结合的抗体和其用途 | |
| US20250011416A1 (en) | Methods for the treatment of cardiovascular disease | |
| WO2023116751A1 (zh) | 抗人血管生成素3纳米抗体及其应用 | |
| CN117159703B (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| WO2022261846A1 (zh) | 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用 | |
| WO2024099310A1 (zh) | 抗il-13长效纳米抗体序列及其应用 | |
| KR20230167968A (ko) | 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형 | |
| RU2845158C1 (ru) | Способы лечения атопического дерматита путем введения антагониста il-4r | |
| CN117982437A (zh) | 一种靶向冠状病毒的抗体制剂及其应用 | |
| HK40088389B (en) | Bispecific antibodies against folr1 and uses thereof | |
| HK40088389A (en) | Bispecific antibodies against folr1 and uses thereof | |
| WO2025233445A1 (en) | Treatment of head and neck atopic dermatitis | |
| HK40102408B (en) | Pharmaceutical composition containing anti-lag-3 antibody and application thereof |